Gemina Laboratories Ltd. (TSE:GLAB) has released an update.
Gemina Laboratories Ltd. reports significant strides in their H1 2024 strategic plan, with the signing of their first technology license and maiden commercial revenues. The company has partnered with a major global diagnostics firm, validating its technology and is now engaged in discussions with four more diagnostic companies, indicating a potential to tap into a substantial market share. Additionally, Gemina’s innovation in lateral flow diagnostics continues to grow, with new solutions and a portfolio of 34 related inventions promising to enhance diagnostic accuracy and reduce costs.
For further insights into TSE:GLAB stock, check out TipRanks’ Stock Analysis page.
